NADIM ADJUVANT Trial Highlights Advantages of Chemo-Immunotherapy After Surgery in Stage IB–IIIA NSCLC
Interim findings from the NADIM ADJUVANT Phase III clinical trial conducted by the Spanish Lung Cancer Group (GECP) have unveiled ...
Tag: minimal residual disease (MRD)
POPULAR NEWS
-
Paclitaxel in Proteinoid Microspheres Produces Complex Bioelectrical Oscillations and Fibrous Networks
-
Dual-Energy CT Visualizes High-Grade Glioma Without Contrast
-
Genomic Evidence Redefines the Evolutionary Position of Enigmatic Freshwater Snail Acrorbis
-
Harvestmen and Cave Wetas Documented Preying on Velvet Worms